| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Biodesix (NASDAQ:BDSX) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1.45) by 2...
																	
																	Biodesix (NASDAQ:BDSX) raises FY2025 sales outlook from $80.000 million-$85.000 million to $84.000 million-$86.000 million vs $...
																	
																	
																	
																	
																	
																	Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $30 to $20.